SCYNEXIS (SCYX) Stock Price, News & Analysis

Company Overview

SCYNEXIS, Inc. is a biotechnology company focused on developing and commercializing medicines for fungal infections. The company’s lead product is BREXAFEMME (ibrexafungerp), an oral, non-azole antifungal approved by the U.S. Food and Drug Administration for the treatment of vulvovaginal candidiasis and for reducing the incidence of recurrent vulvovaginal candidiasis in adult and postmenarchal adolescent females.

Ibrexafungerp is a triterpenoid antifungal that works by inhibiting glucan synthase, an enzyme required for the formation of fungal cell walls. SCYNEXIS has also investigated the medicine for other serious fungal infections, including invasive candidiasis and certain infections caused by drug-resistant fungi. The company’s development strategy has centered on addressing unmet needs where existing antifungal therapies may be limited by resistance, tolerability, drug interactions, or routes of administration.

Founded in 1999 and headquartered in Jersey City, New Jersey, SCYNEXIS serves the U.S. market through its commercial activities and has pursued partnerships and regulatory development opportunities internationally. The company’s operations are primarily focused on advancing and supporting ibrexafungerp and related antifungal research.

Key Stats

• Today's Range: $3.66 to $3.90
• 50-Day Range: $3.66 to $5.67
• 52-Week Range: $3.53 to $9.12
• Volume: 54,621 shs
• Average Volume: 562,816 shs
• Market Capitalization: $37.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.00
• Consensus Rating: Hold

SCYNEXIS Stock Analysis - MarketRank™

SCYNEXIS scored higher than 50% of companies evaluated by MarketBeat, and ranked 520th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

SCYNEXIS has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

SCYNEXIS has a consensus price target of $33.00, representing about 768.4% upside from its current price of $3.80.

Amount of Analyst Coverage

SCYNEXIS has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for SCYNEXIS are expected to grow in the coming year, from ($1.60) to ($0.80) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of SCYNEXIS is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of SCYNEXIS is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

SCYNEXIS has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.23% of the float of SCYNEXIS has been sold short.

Short Interest Ratio / Days to Cover

SCYNEXIS has a short interest ratio ("days to cover") of 0.75, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SCYNEXIS has recently increased by 29.27%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SCYNEXIS does not currently pay a dividend.

Dividend Growth

SCYNEXIS does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

6 people have searched for SCYX on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added SCYNEXIS to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SCYNEXIS insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.09% of the stock of SCYNEXIS is held by insiders.

Percentage Held by Institutions

54.37% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/20/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SCYX
• CIK: 1178253
• Web: www.scynexis.com
• Phone: (201) 884-5485
• Fax: 201-884-5490
• Employees: 29
• Year Founded: 2000

Price Target and Rating

• Average Price Target for SCYNEXIS: $33.00
• High Price Target: $33.00
• Low Price Target: $33.00
• Potential Upside/Downside: +768.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.61 million
• Net Margins: N/A
• Pretax Margin: -53.27%
• Return on Equity: -44.15%
• Return on Assets: -32.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.65
• Quick Ratio: 9.65

Sales & Book Value

• Annual Sales: $20.60 million
• Price / Sales: 1.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.07 per share
• Price / Book: 0.42

Miscellaneous

• Outstanding Shares: 9,950,000
• Free Float: 9,543,000
• Market Cap: $37.81 million
• Optionable: Optionable
• Beta: 1.06